Italian medtech SME developing smart ICT systems for pressure ulcer prevention, diagnosis, and monitoring in clinical and care settings.
DOFREN SRL is an Italian medtech SME specializing in smart systems for the prevention and diagnosis of decubitus ulcers (pressure sores), a costly and painful complication affecting bedridden and wheelchair-bound patients. Their core product — the JUMPAIR system — combines an intelligent anti-decubitus mattress or surface with ICT-based monitoring software that tracks pressure distribution, detects early biomarkers of tissue damage, and triggers alerts for clinical staff. Beyond prevention, the system supports treatment and rehabilitation workflows, positioning it as a full-cycle clinical tool rather than a simple pressure-relief device. Their work sits at the intersection of medical hardware, embedded sensing, and clinical software.
Both JUMPAIR Phase 1 (2015) and Phase 2 (2018) center on the development and commercialization of an intelligent anti-decubitus system as the company's core innovation.
JUMPAIR Phase 2 explicitly added ICT monitoring software as a key component, indicating the platform evolved from hardware to an integrated hardware-software solution.
JUMPAIR Phase 2 lists ulcer biomarkers and decubitus ulcer diagnosis among its keyword areas, suggesting a clinical diagnostics layer was added to the prevention system.
Keywords from the Phase 2 project include 'treatment' and 'rehabilitation', indicating the system addresses the full patient pathway beyond initial prevention.
DOFREN's two H2020 projects are in fact a single innovation trajectory — a Phase 1 feasibility study (2015–2016, €50k) followed by a full Phase 2 development project (2018–2020, €1.29M) under the SME Instrument scheme. In the early phase, the focus was narrowly on the concept of a smart anti-decubitus system for diagnosing pressure ulcer risk. By the later phase, the scope had expanded substantially: ICT monitoring software, clinical biomarkers, treatment support, and rehabilitation were all added, reflecting a transition from proof-of-concept to a market-ready clinical platform. The trajectory is linear and coherent — this is a company deepening one specific product, not pivoting.
DOFREN appears to be a single-product company that used EU funding to take its JUMPAIR system from idea to commercial-stage product; any future collaboration would likely be in clinical validation, market expansion, or integration with hospital information systems.
DOFREN operated exclusively as project coordinator under the SME Instrument scheme, which is designed for single-company projects and does not require consortium partners — so the absence of recorded partners reflects the funding mechanism, not a preference for isolation. This means there is very little evidence of how they behave in multi-partner settings. Anyone considering them as a consortium partner should expect a focused, product-oriented contributor rather than an experienced consortium coordinator in the traditional sense.
DOFREN has no recorded consortium partners in the H2020 database, which is expected given that both projects were solo SME Instrument grants. Their collaboration network — if it exists — is not visible from EU project data alone.
DOFREN is highly specialized: they appear to be the developer of a single, well-defined medical device system targeting a specific and underserved clinical problem — pressure ulcer prevention in long-term care and acute hospital settings. Their successful progression from SME Instrument Phase 1 to Phase 2 confirms that their concept passed the EU's commercial viability assessment, which is not trivial. For a consortium needing a niche medtech partner with validated IP in smart patient surface monitoring, DOFREN offers depth in one focused domain rather than broad research capacity.
